COVID-19 and lung cancer: What do we know?
Small retrospective study of 22 lung cancer patients, 14 treated with HCQ+AZ, showing HCQ+AZ mortality relative risk RR 0.57, p = 0.145.
risk of death, 43.0% lower, RR 0.57, p = 0.14, treatment 6 of 14 (42.9%), control 6 of 8 (75.0%), NNT 3.1.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Serrano et al., 22 Sep 2020, retrospective, Spain, peer-reviewed, 8 authors.
Abstract: Annals of Oncology
1765P
abstracts
Developing a risk assessment score for cancer patients during the
COVID-19 pandemic
A. Indini, M. Cattaneo, M. Ghidini, E. Rijavec, C. Bareggi, B. Galassi, D. Gambini,
F. Grossi
Medical Oncology Unit, Ospedale Maggiore Policlinico-Fondazione IRCCS Ca’ Granda,
Milan, Italy
Background: Data on the novel coronavirus (CoV) respiratory disease (COVID-19) in
cancer patients (pts) are limited. In some individuals, CoV infection triggers an
aberrant inflammatory response, leading to lung tissue damage. Cancer pts treated
with immunotherapy (IT) may therefore be more at risk for COVID-19 infection and
related complications.
Methods: We performed a thorough review of the literature on CoV pathogenesis
and cancer, selecting shared features of the two disease entities to develop a riskassessment score to quantify both the risk of infection and the risk implied in cancer
treatment delays.
Results: The score includes clinical and laboratory variables (Table). Pts’ characteristics include: age, presence of comorbidities (hypertension, cardiovascular disease,
diabetes, chronic obstructive pulmonary disease, chronic systemic infections), obesity,
sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and
concomitant steroid treatment (>10 mg daily of prednisone equivalent, lasting for
>1-month period). Disease characteristics include: lung cancer diagnosis, history of
thoracic radiotherapy (RT) (only for pts with extra-thoracic tumours). Treatment
characteristics include: line of treatment, type (IT or combined IT/chemotherapy [CT]
considered high-risk, followed by CT, and other anticancer drugs), history of immunerelated adverse events (irAEs). Laboratory tests include: levels of neutrophil-to-lymphocite ratio (NLR), lactate-dehydrogenase (LDH), and C-reactive protein (CRP). Based
on the resulting score, pts can be divided in the following categories of risk: low
(score <4), intermediate (score 4-6), and high risk (score >7).
Table: 1765P The “Milano Policlinico ONCOVID Score” for risk evaluation in
oncology during COVID-19
Variables
Score
Sex
ECOG PS
Age
BMI
Comorbidities
Concomitant steroid
treatment
Thoracic tumour
History of thoracic RT
Line of cancer treatment
Type of treatment
F¼0M¼1
0 - 1 ¼ 0 2, or higher ¼ 1
< 70 ¼ 0 70, or higher ¼ 1
< 30 ¼ 0 30, or higher ¼ 1
NO ¼ 0 YES ¼ 1 Yes, >1 ¼ 2
NO ¼ 0 YES ¼ 1
History of irAEs
NLR
LDH
CRP
NO ¼ 0 YES ¼ 1
NO ¼ 0 YES ¼ 1
adjuvant ¼ 0 1st, or more ¼ 1
hormone therapy, targeted therapy, monoclonal
antibodies ¼ 0 CT ¼ 1 IT/IT + CT ¼ 2
NO ¼ 0 YES ¼ 1 YES, pneumonitis ¼ 2
< 5 ¼ 0 5, or higher ¼ 1
< ULN ¼ 0 ULN, or higher ¼ 1
< ULN ¼ 0 ULN, or higher ¼ 1
Conclusions: There is a strong rationale supporting the presented data as potential
risk factors for COVID-19 in cancer pts. The present score is currently undergoing
validation on a wide population of cancer pts to confirm its role and potentially help
physicians’ treatment decisions.
Legal entity responsible for the study: The authors.
1766P
COVID-19 and lung cancer: What do we know?
G. Serrano, J. Rogado, C. Pangua, B. Obispo, A. Martin Marino, M. Perez-Perez,
A. Lopez-Alfonso, M.A. Lara
Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
Background: Currently we still have limited information on how COVID-19 infection
has affected lung cancer patients. In our study, we analysed whether there are differences in terms of mortality from COVID-19 between patients..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit